Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up After Earnings Beat

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $28.42, but opened at $30.33. Collegium Pharmaceutical shares last traded at $31.22, with a volume of 40,596 shares traded.

The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on COLL. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 3.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. New Age Alpha Advisors LLC purchased a new stake in Collegium Pharmaceutical during the fourth quarter valued at $40,000. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after buying an additional 483 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at about $72,000. KBC Group NV lifted its holdings in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after acquiring an additional 982 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares in the last quarter.

Collegium Pharmaceutical Trading Up 2.2 %

The company has a 50-day moving average of $30.82 and a 200 day moving average of $33.47. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market cap of $936.86 million, a PE ratio of 12.52 and a beta of 0.82.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.